ZA972719B - Use of rapamycin derivatives in vasculopathies and xenotransplantations - Google Patents

Use of rapamycin derivatives in vasculopathies and xenotransplantations

Info

Publication number
ZA972719B
ZA972719B ZA972719A ZA972719A ZA972719B ZA 972719 B ZA972719 B ZA 972719B ZA 972719 A ZA972719 A ZA 972719A ZA 972719 A ZA972719 A ZA 972719A ZA 972719 B ZA972719 B ZA 972719B
Authority
ZA
South Africa
Prior art keywords
xenotransplantations
vasculopathies
rapamycin derivatives
rapamycin
deoxyspergualine
Prior art date
Application number
ZA972719A
Other languages
English (en)
Inventor
Walter Schuler
Hendrik Schuurman
Gisbert Weckbecker
Hans-Guenther Zerwes
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10791127&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA972719(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ZA972719B publication Critical patent/ZA972719B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA972719A 1996-03-27 1997-03-27 Use of rapamycin derivatives in vasculopathies and xenotransplantations ZA972719B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9606452.2A GB9606452D0 (en) 1996-03-27 1996-03-27 Organic compounds

Publications (1)

Publication Number Publication Date
ZA972719B true ZA972719B (en) 1998-09-28

Family

ID=10791127

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA972719A ZA972719B (en) 1996-03-27 1997-03-27 Use of rapamycin derivatives in vasculopathies and xenotransplantations

Country Status (30)

Country Link
US (5) US6384046B1 (ru)
EP (3) EP1149581A3 (ru)
JP (2) JP2000507226A (ru)
KR (2) KR20070083654A (ru)
CN (1) CN1124135C (ru)
AT (1) ATE224194T1 (ru)
AU (1) AU716514B2 (ru)
BR (1) BR9708358A (ru)
CA (1) CA2247275C (ru)
CY (1) CY2404B1 (ru)
CZ (1) CZ292483B6 (ru)
DE (1) DE69715611T2 (ru)
DK (2) DK2008657T3 (ru)
ES (2) ES2184078T3 (ru)
GB (1) GB9606452D0 (ru)
HK (1) HK1018688A1 (ru)
HU (1) HU226422B1 (ru)
ID (1) ID17195A (ru)
IL (1) IL125812A (ru)
MY (1) MY117798A (ru)
NO (1) NO316667B1 (ru)
NZ (1) NZ331463A (ru)
PL (1) PL187732B1 (ru)
PT (2) PT893996E (ru)
RU (1) RU2214247C2 (ru)
SI (1) SI2008657T1 (ru)
SK (1) SK284343B6 (ru)
TR (1) TR199801919T2 (ru)
WO (1) WO1997035575A1 (ru)
ZA (1) ZA972719B (ru)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9606452D0 (en) * 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds
PT1208847E (pt) 1996-07-30 2007-07-24 Novartis Ag Composições farmacêuticas para o tratamento da rejeição de transplantes, doenças autoimunes ou inflamatórias compreendendo ciclosporina a e 40-0-(2-hidroxietil)-rapamicina
US6890546B2 (en) 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
ATE474590T1 (de) 1999-05-10 2010-08-15 Paolo Brenner Kombination von immunsuppressiven substanzen zur behandlung oder vorbeugung von transplantat abstossungen
US6790228B2 (en) 1999-12-23 2004-09-14 Advanced Cardiovascular Systems, Inc. Coating for implantable devices and a method of forming the same
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
US7807211B2 (en) 1999-09-03 2010-10-05 Advanced Cardiovascular Systems, Inc. Thermal treatment of an implantable medical device
EP1263484B1 (en) 2000-03-15 2007-05-16 OrbusNeich Medical, Inc. Coating which promotes endothelial cell adherence
US20070141107A1 (en) * 2000-03-15 2007-06-21 Orbusneich Medical, Inc. Progenitor Endothelial Cell Capturing with a Drug Eluting Implantable Medical Device
US20070055367A1 (en) * 2000-03-15 2007-03-08 Orbus Medical Technologies, Inc. Medical device with coating that promotes endothelial cell adherence and differentiation
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
US8460367B2 (en) * 2000-03-15 2013-06-11 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US20030229393A1 (en) * 2001-03-15 2003-12-11 Kutryk Michael J. B. Medical device with coating that promotes cell adherence and differentiation
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US8236048B2 (en) 2000-05-12 2012-08-07 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
US20050002986A1 (en) * 2000-05-12 2005-01-06 Robert Falotico Drug/drug delivery systems for the prevention and treatment of vascular disease
US20020013335A1 (en) * 2000-06-16 2002-01-31 American Home Products Corporation Method of treating cardiovascular disease
EP1709974A3 (en) * 2000-06-16 2006-12-06 Wyeth Method of treating cardiovascular disease using rapamycin
US6670355B2 (en) 2000-06-16 2003-12-30 Wyeth Method of treating cardiovascular disease
CA2424029C (en) 2000-09-29 2008-01-29 Cordis Corporation Coated medical devices
PT2762140T (pt) 2001-02-19 2017-07-04 Novartis Ag Resumo
US8741378B1 (en) 2001-06-27 2014-06-03 Advanced Cardiovascular Systems, Inc. Methods of coating an implantable device
US6939376B2 (en) 2001-11-05 2005-09-06 Sun Biomedical, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US7682387B2 (en) 2002-04-24 2010-03-23 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US20040024450A1 (en) * 2002-04-24 2004-02-05 Sun Biomedical, Ltd. Drug-delivery endovascular stent and method for treating restenosis
WO2003099169A1 (en) * 2002-05-20 2003-12-04 Orbus Medical Technologies Inc. Drug eluting implantable medical device
US8109987B2 (en) 2003-04-14 2012-02-07 Tryton Medical, Inc. Method of treating a lumenal bifurcation
US7279174B2 (en) 2003-05-08 2007-10-09 Advanced Cardiovascular Systems, Inc. Stent coatings comprising hydrophilic additives
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
US7220755B2 (en) * 2003-11-12 2007-05-22 Biosensors International Group, Ltd. 42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same
US9114198B2 (en) 2003-11-19 2015-08-25 Advanced Cardiovascular Systems, Inc. Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same
WO2005107817A2 (en) * 2004-04-30 2005-11-17 Orbus Medical Technologies, Inc. Medical device with coating for capturing genetically-altered cells and methods of using same
US20110104186A1 (en) 2004-06-24 2011-05-05 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
US8709469B2 (en) 2004-06-30 2014-04-29 Abbott Cardiovascular Systems Inc. Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device
US7901451B2 (en) 2004-09-24 2011-03-08 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method for treating restenosis
EP1838288A4 (en) * 2004-12-20 2010-08-04 Ariad Pharma Inc THERAPEUTIC MATERIALS AND METHODS
WO2007059106A2 (en) 2005-11-14 2007-05-24 Ariad Gene Therapeutics, Inc. Administration of mntor inhibitor to treat patients with cancer
WO2007058399A1 (en) * 2005-11-17 2007-05-24 Access Plus Co., Ltd A tube for connecting marteriovenous and interposition for medical operation
US20070173923A1 (en) * 2006-01-20 2007-07-26 Savage Douglas R Drug reservoir stent
EP2702993B1 (en) 2006-09-13 2017-12-06 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
US20080097591A1 (en) * 2006-10-20 2008-04-24 Biosensors International Group Drug-delivery endovascular stent and method of use
US8067055B2 (en) * 2006-10-20 2011-11-29 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method of use
US20080103584A1 (en) 2006-10-25 2008-05-01 Biosensors International Group Temporal Intraluminal Stent, Methods of Making and Using
KR100930167B1 (ko) * 2007-09-19 2009-12-07 삼성전기주식회사 초광각 광학계
US8661630B2 (en) 2008-05-21 2014-03-04 Abbott Cardiovascular Systems Inc. Coating comprising an amorphous primer layer and a semi-crystalline reservoir layer
JP5693228B2 (ja) 2007-11-14 2015-04-01 バイオセンサーズ インターナショナル グループ、リミテッド 自動被覆装置および方法
CA2711765A1 (en) * 2008-01-11 2009-07-16 Massachusetts Eye & Ear Infirmary Conditional-stop dimerizable caspase transgenic animals
KR20110074758A (ko) * 2008-10-03 2011-07-01 엘릭서 메디컬 코포레이션 마크로사이클릭 락톤 화합물 및 이를 사용하는 방법
US8382818B2 (en) 2009-07-02 2013-02-26 Tryton Medical, Inc. Ostium support for treating vascular bifurcations
US8685433B2 (en) 2010-03-31 2014-04-01 Abbott Cardiovascular Systems Inc. Absorbable coating for implantable device
UA104738C2 (ru) 2011-05-18 2014-03-11 Олег Миколайович Лазаренко Композиция для повышения биосовместимости имплантатов и клеток для трансплантации с организмом реципиента и способ ее приготовления
CN102268015B (zh) * 2011-08-30 2013-08-28 成都摩尔生物医药有限公司 一种依维莫司的合成方法
US10682415B2 (en) 2013-07-22 2020-06-16 Wisconsin Alumni Research Foundation Thermogel formulation for combination drug delivery
KR101723265B1 (ko) 2013-08-16 2017-04-04 가톨릭대학교 산학협력단 mTOR/STAT3 신호억제제 처리된 면역조절능을 갖는 간엽줄기세포 및 이를 포함하는 면역질환의 예방 또는 치료용 세포치료제 조성물
CA2924681C (en) 2013-09-24 2019-12-31 Giner, Inc. System for gas treatment of a cell implant
EP3054948B1 (en) 2013-10-08 2020-08-12 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
EP3104891A1 (en) 2014-02-11 2016-12-21 Lam Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
US10307371B2 (en) 2014-02-11 2019-06-04 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
BR112016022598A8 (pt) 2014-04-04 2021-06-29 Ai Therapeutics Inc composição aerossol farmacêutica na forma de um pó seco para liberação pulmonar, forma de dosagem unitária, pacote farmacêutico, kit e uso
EP3209330B1 (en) 2014-10-07 2022-02-23 AI Therapeutics, Inc. An inhalable sirolimus formulation for the treatment of pulmonary hypertension
MA40910A (fr) 2014-11-07 2017-09-12 Civitas Therapeutics Inc Poudres de rapamycine pour administration pulmonaire
WO2016130645A1 (en) 2015-02-10 2016-08-18 Lam Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
JP2019527711A (ja) 2016-08-10 2019-10-03 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 局所ラパマイシン療法
EP3515517B1 (en) 2016-09-19 2022-02-16 Biotronik AG Polymer-free drug eluting vascular stents
US11033666B2 (en) 2016-11-15 2021-06-15 Giner Life Sciences, Inc. Percutaneous gas diffusion device suitable for use with a subcutaneous implant
US11826492B2 (en) 2016-12-22 2023-11-28 Biotronik Ag Intratumoral drug delivery materials and methods for treating breast cancer
US11642501B2 (en) 2017-05-04 2023-05-09 Giner, Inc. Robust, implantable gas delivery device and methods, systems and devices including same
UY37900A (es) 2017-09-26 2019-04-30 Novartis Ag Nuevos derivados de rapamicina
BR112021016296A2 (pt) 2019-02-20 2021-11-09 Ai Therapeutics Inc Formulações tópicas de rapamicina e seu uso em tratamento de angiofibromas faciais e outros distúrbios de pele

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639724A (en) * 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
US5364612A (en) * 1991-05-06 1994-11-15 Immunomedics, Inc. Detection of cardiovascular lesions
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
CA2086642C (en) * 1992-01-09 2004-06-15 Randall E. Morris Method of treating hyperproliferative vascular disease
KR100284210B1 (ko) * 1992-04-28 2001-03-02 이건 이. 버그 과증식성 혈관 질환 치료용 배합 제제
US5747034A (en) * 1992-07-09 1998-05-05 Chiron Corporation Methods and materials for the induction of T cell anergy
US5283257A (en) * 1992-07-10 1994-02-01 The Board Of Trustees Of The Leland Stanford Junior University Method of treating hyperproliferative vascular disease
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
SK78196A3 (en) * 1993-12-17 1997-02-05 Sandoz Ag Rapamycin demethoxy-derivatives, preparation method thereof and pharmaceutical agent containing them
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US6265427B1 (en) * 1995-06-07 2001-07-24 The Proctor & Gamble Company Pharmaceutical composition for the method of treating leukemia
AU712193B2 (en) * 1995-06-09 1999-10-28 Novartis Ag Rapamycin derivatives
GB9606452D0 (en) * 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds

Also Published As

Publication number Publication date
AU2291897A (en) 1997-10-17
AU716514B2 (en) 2000-02-24
CN1214631A (zh) 1999-04-21
NZ331463A (en) 2001-10-26
CZ292483B6 (cs) 2003-09-17
HU226422B1 (en) 2008-12-29
DK2008657T3 (da) 2013-07-22
EP0893996A1 (en) 1999-02-03
CA2247275C (en) 2011-10-11
WO1997035575A1 (en) 1997-10-02
US20020127248A1 (en) 2002-09-12
RU2214247C2 (ru) 2003-10-20
PT893996E (pt) 2002-12-31
IL125812A0 (en) 1999-04-11
IL125812A (en) 2001-12-23
EP1149581A2 (en) 2001-10-31
SK284343B6 (sk) 2005-02-04
EP2008657A2 (en) 2008-12-31
TR199801919T2 (xx) 1999-02-22
US20120177690A1 (en) 2012-07-12
BR9708358A (pt) 1999-08-03
KR20050038656A (ko) 2005-04-27
EP2008657A3 (en) 2009-02-04
EP0893996B1 (en) 2002-09-18
DE69715611D1 (de) 2002-10-24
ES2421455T3 (es) 2013-09-02
JP2009102349A (ja) 2009-05-14
GB9606452D0 (en) 1996-06-05
CN1124135C (zh) 2003-10-15
NO316667B1 (no) 2004-03-29
NO984340L (no) 1998-09-18
HUP0001267A2 (hu) 2000-11-28
US20100152105A1 (en) 2010-06-17
ES2184078T3 (es) 2003-04-01
DK0893996T3 (da) 2002-12-09
SK132798A3 (en) 1999-03-12
HK1018688A1 (en) 1999-12-30
JP2000507226A (ja) 2000-06-13
PL328659A1 (en) 1999-02-15
SI2008657T1 (sl) 2013-07-31
PT2008657E (pt) 2013-07-12
EP2008657B1 (en) 2013-04-24
KR20070083654A (ko) 2007-08-24
NO984340D0 (no) 1998-09-18
HUP0001267A3 (en) 2002-01-28
DE69715611T2 (de) 2003-05-22
MY117798A (en) 2004-08-30
CY2404B1 (en) 2004-09-10
KR100836971B1 (ko) 2008-06-10
EP1149581A3 (en) 2003-12-03
CZ307098A3 (cs) 1999-01-13
ATE224194T1 (de) 2002-10-15
JP5124431B2 (ja) 2013-01-23
ID17195A (id) 1997-12-11
PL187732B1 (pl) 2004-09-30
CA2247275A1 (en) 1997-10-02
US6384046B1 (en) 2002-05-07
US20140187574A1 (en) 2014-07-03

Similar Documents

Publication Publication Date Title
CY2404B1 (en) Use of rapamycin derivatives in vasculopathies andxenotransplantation.
IL140137A0 (en) Receptor bodies specifically binding tie-2 ligands
TW249198B (en) Stents for autologous tissue heart valve
DE69205845D1 (de) Katalysatorträger, zusammensetzung und Verfahren zu seiner Herstellung.
MX9603479A (es) Derivados de 4-amino de acido micofenolico con actividad inmunosupresora.
ES2184800T3 (es) Uso de agentes anti-vegf en el tratamiento de la endometriosis.
PT922071E (pt) Copolimeros reticulados a base de polimeros policarboxilicos
WO2003101919A3 (en) Scorpionate-like pendant macrocyclic ligands, complexes and compositions thereof, and methods of using same
Giakas Risperidone treatment for a Tourette's disorder patient with comorbid obsessive-compulsive disorder.
DE69522564D1 (de) Alkalibeständiges proteinadsorbens
DE602004017838D1 (de) Verfahren zur herstellung von 6-ä(4,5-dihydro-1h-imidazol-2-yl)amino-ü-7-methyl-1h-benzimidazol-4-carbonitrile und dessen bevorzugte salzform
DK0745071T3 (da) 4-Amino-6-substitueret mycophenolsyre og derivater med immunsuppressiv virkning
HK1010784A1 (en) 4-amino derivatives of 5-substituted mycophenolic acid
Pioli Reactivation failure in infants: A processing analysis.
IT1241270B (it) Procedimento per realizzare vaschette di contenimento per cuscini, particolarmente cuscini di sedili per autoveicoli.
UA36539A (ru) Способ проведения тренировок, основанных на перемещениях пациента и комплекс средств для его осуществления
ES1022409U (es) Soporte para ceniceros, posavasos y similares desechables o no desechables.
IT9053024U1 (it) Sedile per tazza di w. c. dotato di dispositivo di riscaldamento, di as pirazione e filtrazione